Coronavirus company news summary – Inovio expands Covid-19 vaccine global manufacturing capacity – Daewoong eyes Phase II studies of anti-parasitic drug

4 December 2020 (Last Updated December 4th, 2020 09:03)

4 December 2020 

Senhwa Biosciences announced that the first patient had been enrolled into its Phase II investigator-initiated trial (IIT) of silmitasertib, an investigational drug for the treatment of Covid-19 . The trial is being conducted at the Centre for Advanced Research and Education (CARE) in the US state of Georgia.

Inovio announced an agreement with Kaneka Eurogentec, a global plasmid manufacturer, to support the manufacturing of INOVIO’s INO-4800, its Covid-19 vaccine candidate. Kaneka joins Richter-Helm BioLogics, Thermo Fisher Scientific, and Ology Biosciences in the company’s global manufacturing consortium, and will fulfil its global manufacturing needs across its vaccines and DNA medicines portfolios.

Indonesia-based Universitas Gadjah Mada has entered into a partnership with PT Philippines Antiviral Indonesia to develop an antiviral drug for Covid-19. Although the drug development has commenced, Indonesia‘s Food and Drug Authority is yet to approve the drug for clinical trials.

Daewoong Pharma has sought regulatory approval from South Korea’s food and drug safety ministry to conduct Phase II trials of its anti-parasite niclosamide drug, DWRX2003, for treating Covid-19 . Around 200 infected patients will participate in the trials, the company announced.